Effective January 1, 2015, Novolin, Novolog, Lantus and Levemir will be the insulin products with preferred status for Commercial and Exchange Market formularies.

Blue Cross and Blue Shield of Alabama, Blue Cross and Blue Shield of Kansas, Blue Cross Blue Shield of Wyoming, Blue Cross and Blue Shield of Minnesota, Blue Cross and Blue Shield of Nebraska, Minnesota, Florida Blue, Blue Cross Blue Shield North Dakota, and Horizon BCBSNJ Formulary and Utilization Management Change